Want to see TSE:HEM full AI Analyst Report?
HEM Stock Chart & Stats
C$0.08
C$0.03(23.81%)
At close: 4:00 PM EST
C$0.08
C$0.03(23.81%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.14
Previous CloseN/A
Volume356.00K
Average Volume (3M)138.35K
Market Cap
C$11.87M
Enterprise ValueC$14.32M
Total Cash (Recent Filing)C$319.24K
Total Debt (Recent Filing)C$3.62M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding197,796,450
10 Day Avg. Volume155,944
30 Day Avg. Volume138,348
Financial Highlights & Ratios
PEG Ratio-0.66
Price to Book (P/B)-2.96
Price to Sales (P/S)0.00
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Autologous Cell Therapy PlatformThe company's autologous cell-therapy platform targets ischemic and cardiovascular indications, a high-barrier area requiring specialized manufacturing and clinical expertise. Platform focus can create durable differentiation, patient-specific value propositions, and long development/market entry lead times versus commodity competitors.
Lean Operating StructureA very small headcount implies a lean cost base and operational agility typical of early-stage biotech. This structural frugality can extend runway per dollar raised and allow focused allocation to core clinical programs, reducing non-core overhead and preserving capital for R&D execution.
Debt Levels Contained RecentlyReported debt has remained roughly steady rather than spiking, suggesting some funding discipline or controlled borrowing. In a pre-revenue biotech, stable nominal debt reduces sudden leverage shocks and gives management more time to pursue strategic financing or partnerships without immediate default risk.
Bears Say
No Revenue And Widening LossesPersistent zero revenue combined with widening operating and net losses means the company cannot self-fund development or validate commercial traction. Over months this increases dependency on external capital, raises dilution risk, and constrains the ability to scale trials or invest in commercialization infrastructure.
Negative Shareholders' EquityNegative equity and a shrinking asset base materially weaken balance-sheet resilience. This structural deficit limits borrowing capacity, can deter strategic partners or lenders, and heightens the probability that future financing must come via dilutive equity or onerous terms, impacting long-term strategic flexibility.
Chronic Negative Cash Flow And Rising BurnSustained negative operating cash flow and an accelerating cash-burn profile create ongoing liquidity pressure. Over a multi-month horizon this necessitates frequent financing, can force compressed timelines for clinical milestones, and may limit the firm's ability to negotiate favorable partner or supplier terms.
Hemostemix News
HEM FAQ
What was Hemostemix Inc’s price range in the past 12 months?
Hemostemix Inc lowest stock price was C$0.04 and its highest was C$0.14 in the past 12 months.
What is Hemostemix Inc’s market cap?
Hemostemix Inc’s market cap is C$11.87M.
When is Hemostemix Inc’s upcoming earnings report date?
Hemostemix Inc’s upcoming earnings report date is Aug 31, 2026 which is in 37 days.
How were Hemostemix Inc’s earnings last quarter?
Currently, no data Available
Is Hemostemix Inc overvalued?
According to Wall Street analysts Hemostemix Inc’s price is currently Overvalued.
Does Hemostemix Inc pay dividends?
Hemostemix Inc does not currently pay dividends.
What is Hemostemix Inc’s EPS estimate?
Hemostemix Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemostemix Inc have?
Hemostemix Inc has 197,796,450 shares outstanding.
What happened to Hemostemix Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hemostemix Inc?
Currently, no hedge funds are holding shares in TSE:HEM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.